 |
|
Six Years of High-Level Levodopa Therapy in Severely Akinetic Parkinsonian Patients
André Barbeau, MD, FRCP(C)
Arch Neurol. 1976;33(5):333-338.
Abstract
• The clinical course and the side effects of high-level levodopa therapy over a six-year period were studied in 80 severely akinetic parkinsonian patients treated for the first time before June 1968. Levodopa improved the quality of life in greater than 53% of patients, but failed to modify the progression of the disease or change the prognosis. Seventeen "idiopathic Parkinson" patients died after a duration of illness of 9.5 years. Despite the drawbacks, levodopa is still the best available treatment for akinetic parkinsonism.
Author Affiliations
From the Department of Neurobiology, Clinical Research Institute of Montreal, the Department of Medicine, University of Montreal, and the Hôtel-Dieu Hospital, Montreal.
Footnotes
Accepted for publication March 25, 1975.
Reprint requests to Clinical Research Institute of Montreal, 110 Pine Ave W, Montreal, Quebec, Canada H2W 1R7 (Dr Barbeau).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Estimated life expectancy of Parkinson's patients compared with the UK population
Ishihara et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:1304-1309.
ABSTRACT
| FULL TEXT
Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort
Marras et al.
Neurology 2005;64:87-93.
ABSTRACT
| FULL TEXT
Freezing of gait in PD: Prospective assessment in the DATATOP cohort
Giladi et al.
Neurology 2001;56:1712-1721.
ABSTRACT
| FULL TEXT
Mortality from Parkinson's disease
CLARKE
J. Neurol. Neurosurg. Psychiatry 2000;68:254-255.
FULL TEXT
The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years
Hely et al.
J. Neurol. Neurosurg. Psychiatry 1999;67:300-307.
ABSTRACT
| FULL TEXT
From off-period dystonia to peak-dose chorea: The clinical spectrum of varying subthalamic nucleus activity
Krack et al.
Brain 1999;122:1133-1146.
ABSTRACT
| FULL TEXT
|
